^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    High ALC

    1m
    Baseline absolute lymphocyte count as a prognostic indicator in advanced or metastatic breast cancer: a systematic review and meta-analysis. (PubMed, Am J Transl Res)
    Subgroup analysis was conducted on chemotherapy regimens, with and without eribulin. Despite variations in chemotherapy regimens, patients with ABC or MBC and high ALC exhibited longer PFS and PPS (HR = 0.45, 95% CI: 0.30-0.67, P < 0.0001), PFS and TTF (HR = 0.39, 95% CI: 0.20-0.78, P = 0.008), and OS (HR = 0.71, 95% CI: 0.62-0.82, P < 0.00001; HR = 0.5, 95% CI: 0.35-0.70, P < 0.0001). The results of this meta-analysis suggest that baseline ALC, as an immune marker, can serve as an effective prognostic indicator for ABC or MBC.
    Retrospective data • Review • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • EGFR positive • High ALC
    |
    Halaven (eribulin mesylate)
    2ms
    Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer. (PubMed, Int J Clin Oncol)
    NLR at EOT with CDK4/6 inhibitors is a significant and independent prognostic marker for patients with ER-positive HER2-negative advanced breast cancer.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR positive • High NLR • ER positive + HER-2 negative • High ALC • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant
    7ms
    Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. (PubMed, Sci Rep)
    There was no significant difference in efficacy between abemaciclib and palbociclib and both had good safety profiles. We demonstrated that ALC and NLR might predict the outcomes of CDK4/6i treatment in patients with ER + HER2 - ABC.
    Retrospective data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • High NLR • High ALC
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)
    7ms
    Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia. (PubMed, Hematol Oncol Stem Cell Ther)
    Although clarity on clinical behavior with regard to initiation of treatment remains elusive, IPS-E and AIPS-E are valuable tools for identifying high-risk patients.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation • High ALC
    11ms
    A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors. (PubMed, J Cancer Res Clin Oncol)
    In our meta-analysis, different immune checkpoint factors were associated with different prognoses in HNSCC patients receiving immunotherapy. HPV, PD-L1, BMI, Alb, HPD, PS, GPS/mGPS, LDH, NLR, and PLR predicted the ICI outcome in HNSCC patients.
    Retrospective data • Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    Low NLR • LDH-L • Low PLR • High ALC
    1year
    Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies (ASH 2023)
    Paradoxically, this better immune status may interfere with allogeneic T lymphocytes by reducing the graft-versus-leukemia effect. Thus, increasing immunosuppression (via the conditioning or drugs used for GVHD prophylaxis) may improve outcome in some specific sub-groups of patients with higher autologous T lymphocytes at transplant.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    High ALC
    1year
    Factors Influencing Lymphocyte Collection Efficiency for the Manufacture of CAR-T Cells in Adults with B Cell Malignancies , a Single Center Experience (ASH 2023)
    High efficiency leukapheresis is safe and feasible in autologous T-cell donors. Our data also confirms that high ALC and peripheral blood CD3 counts pre-apheresis are strongly correlated to the CD3 yield in the product. Our centre now uses a CE estimate of 60% for collection of CAR T starting material.
    Clinical • CAR T-Cell Therapy
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    High ALC
    1year
    Impact of "Cell-of-Origin" on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas (ASH 2023)
    We could not confirm an association between COO, as determined by Hans algorithm, and outcomes in R/R aNHLs who received axi-cel at our center. Prospective analyses on larger datasets and other types of CAR-T products are needed.
    CAR T-Cell Therapy • IO biomarker
    |
    BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    LDH elevation • High ALC
    |
    Yescarta (axicabtagene ciloleucel)